Zoetis Inc. Revenue by Geography
No Revenue by Geography for ZTS on this site yet.
- 2025-12-31: Others Not split by product in the filing$9.47B100.00%; Total revenue $9.47B.
- 2024-12-31: Others Not split by product in the filing$9.26B100.00%; Total revenue $9.26B.
- 2023-12-31: Others Not split by product in the filing$8.54B100.00%; Total revenue $8.54B.
- 2022-12-31: Others Not split by product in the filing$8.08B100.00%; Total revenue $8.08B.
Source checked: the stored Revenue by Geography page for ZTS.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $9.47B 100.00% | $9.47B |
| 2024-12-31 | Not split by product in the filing $9.26B 100.00% | $9.26B |
| 2023-12-31 | Not split by product in the filing $8.54B 100.00% | $8.54B |
| 2022-12-31 | Not split by product in the filing $8.08B 100.00% | $8.08B |
| 2021-12-31 | Not split by product in the filing $7.78B 100.00% | $7.78B |
| 2020-12-31 | Not split by product in the filing $6.67B 100.00% | $6.67B |
| 2019-12-31 | Not split by product in the filing $6.26B 100.00% | $6.26B |
| 2018-12-31 | Not split by product in the filing $5.83B 100.00% | $5.83B |
| 2017-12-31 | Not split by product in the filing $5.31B 100.00% | $5.31B |
| 2016-12-31 | Not split by product in the filing $4.89B 100.00% | $4.89B |
| 2015-12-31 | Not split by product in the filing $4.76B 100.00% | $4.76B |
| 2014-12-31 | Not split by product in the filing $4.79B 100.00% | $4.79B |
| 2013-12-31 | Not split by product in the filing $4.56B 100.00% | $4.56B |
| 2012-12-31 | Not split by product in the filing $4.34B 100.00% | $4.34B |
| 2011-12-31 | Not split by product in the filing $4.23B 100.00% | $4.23B |
Each quarter (3 month)
| Quarter end | Total Products and Services | Contract Manufacturing and Human Health Diagnostics | Others | Total revenue |
|---|---|---|---|---|
| 2026-06-30 | $2.44B 98.82% | $29.00M 1.18% | $2.47B | |
| 2026-03-31 | Not split by product $2.26B 100.00% | $2.26B | ||
| 2025-12-31 | Not split by product $2.39B 100.00% | $2.39B | ||
| 2025-09-30 | Not split by product $2.40B 100.00% | $2.40B | ||
| 2025-06-30 | $2.44B 98.67% | $33.00M 1.33% | $2.47B | |
| 2025-03-31 | Not split by product $2.20B 100.00% | $2.20B | ||
| 2024-12-31 | Not split by product $2.32B 100.00% | $2.32B | ||
| 2024-09-30 | Not split by product $2.39B 100.00% | $2.39B | ||
| 2024-06-30 | Not split by product $2.36B 100.00% | $2.36B | ||
| 2024-03-31 | Not split by product $2.19B 100.00% | $2.19B | ||
| 2023-12-31 | Not split by product $2.21B 100.00% | $2.21B | ||
| 2023-09-30 | Not split by product $2.15B 100.00% | $2.15B | ||
| 2023-06-30 | Not split by product $2.18B 100.00% | $2.18B | ||
| 2023-03-31 | Not split by product $2.00B 100.00% | $2.00B | ||
| 2022-12-31 | Not split by product $2.04B 100.00% | $2.04B | ||
| 2022-09-30 | Not split by product $2.00B 100.00% | $2.00B | ||
| 2022-06-30 | Not split by product $2.05B 100.00% | $2.05B | ||
| 2022-03-31 | Not split by product $1.99B 100.00% | $1.99B | ||
| 2021-12-31 | Not split by product $1.97B 100.00% | $1.97B | ||
| 2021-09-30 | Not split by product $1.99B 100.00% | $1.99B | ||
| 2021-06-30 | Not split by product $1.95B 100.00% | $1.95B | ||
| 2021-03-31 | Not split by product $1.87B 100.00% | $1.87B | ||
| 2020-12-31 | Not split by product $1.81B 100.00% | $1.81B | ||
| 2020-09-30 | Not split by product $1.79B 100.00% | $1.79B | ||
| 2020-06-30 | Not split by product $1.55B 100.00% | $1.55B | ||
| 2020-03-31 | Not split by product $1.53B 100.00% | $1.53B | ||
| 2019-12-31 | Not split by product $1.67B 100.00% | $1.67B | ||
| 2019-09-30 | Not split by product $1.58B 100.00% | $1.58B | ||
| 2019-06-30 | Not split by product $1.55B 100.00% | $1.55B | ||
| 2019-03-31 | Not split by product $1.46B 100.00% | $1.46B | ||
| 2018-12-31 | Not split by product $1.56B 100.00% | $1.56B | ||
| 2018-09-30 | Not split by product $1.48B 100.00% | $1.48B | ||
| 2018-06-30 | Not split by product $1.42B 100.00% | $1.42B | ||
| 2018-03-31 | Not split by product $1.37B 100.00% | $1.37B | ||
| 2017-12-31 | Not split by product $1.46B 100.00% | $1.46B | ||
| 2017-10-01 | Not split by product $1.35B 100.00% | $1.35B | ||
| 2017-07-02 | Not split by product $1.27B 100.00% | $1.27B | ||
| 2017-04-02 | Not split by product $1.23B 100.00% | $1.23B | ||
| 2016-12-31 | Not split by product $1.28B 100.00% | $1.28B | ||
| 2016-10-02 | Not split by product $1.24B 100.00% | $1.24B | ||
| 2016-07-03 | Not split by product $1.21B 100.00% | $1.21B | ||
| 2016-04-03 | Not split by product $1.16B 100.00% | $1.16B | ||
| 2015-12-31 | Not split by product $1.27B 100.00% | $1.27B | ||
| 2015-09-27 | Not split by product $1.21B 100.00% | $1.21B | ||
| 2015-06-28 | Not split by product $1.18B 100.00% | $1.18B | ||
| 2015-03-29 | Not split by product $1.10B 100.00% | $1.10B | ||
| 2014-12-31 | Not split by product $1.32B 100.00% | $1.32B | ||
| 2014-09-28 | Not split by product $1.21B 100.00% | $1.21B | ||
| 2014-06-29 | Not split by product $1.16B 100.00% | $1.16B | ||
| 2014-03-30 | Not split by product $1.10B 100.00% | $1.10B | ||
| 2013-12-31 | Not split by product $1.25B 100.00% | $1.25B | ||
| 2013-09-29 | Not split by product $1.10B 100.00% | $1.10B | ||
| 2013-06-30 | Not split by product $1.11B 100.00% | $1.11B | ||
| 2013-03-31 | Not split by product $1.09B 100.00% | $1.09B | ||
| 2012-12-31 | Not split by product $1.18B 100.00% | $1.18B | ||
| 2012-09-30 | Not split by product $1.02B 100.00% | $1.02B | ||
| 2012-07-01 | Not split by product $1.09B 100.00% | $1.09B | ||
| 2012-04-01 | Not split by product $1.05B 100.00% | $1.05B |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |